In 2013, we offered Soliris to a growing number of individuals with PNH and aHUS worldwide. We demonstrated stable growth in PNH, grew steadily the amount of new sufferers with aHUS receiving Soliris in the U.S. And the 1st countries of Western European countries, and began serving initial patients with aHUS in Japan, said Leonard Bell, M.D., CEO of Alexion. Throughout 2014, we shall focus on serving more patients with PNH and aHUS globally. Simultaneously, we will advance our business lead pipeline initiatives toward achieving ten or more advancement milestones as we travel toward our anticipated group of as many as seven potential product approvals between 2014 and 2018..
$10.3 million biodefense contract to deal with salmonella, typhoid monkey and fever pox virus Pacific Northwest Nationwide Laboratory has received a $10.3 million biodefense contract from the Nationwide Institute of Allergy symptoms and Infectious Agents to identify the proteins that regulate the bacterias that trigger salmonella poisoning and typhoid fever, and the monkey pox virus. The five-year award is the Division of Energy lab’s third $10 million National Institutes of Health grant or contract in the past year and the second for Richard D. Smith, principal investigator and a Battelle Fellow at PNNL.